Pharmena S.A. (PHR) - Total Liabilities

Latest as of September 2025: zł850.00K PLN ≈ $233.93K USD

Based on the latest financial reports, Pharmena S.A. (PHR) has total liabilities worth zł850.00K PLN (≈ $233.93K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Pharmena S.A. liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Pharmena S.A. - Total Liabilities Trend (2008–2024)

This chart illustrates how Pharmena S.A.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see PHR asset base.

Pharmena S.A. Competitors by Total Liabilities

The table below lists competitors of Pharmena S.A. ranked by their total liabilities.

Company	Country	Total Liabilities
Dynaciate Group Bhd KLSE:5178	Malaysia	RM51.94 Million
ESSA Pharma Inc NASDAQ:EPIX	USA	$1.60 Million
Viking Mines Ltd AU:VKA	Australia	AU$370.98K
Knusford Bhd KLSE:5035	Malaysia	RM156.80 Million
Ebang International Holdings NASDAQ:EBON	USA	$8.37 Million
Bawat Water Technologies AB ST:BAWAT	Sweden	Skr28.66 Million
Finsbury Growth & Income Trust LSE:FGT	UK	GBX34.10 Million
Mainz Biomed BV NASDAQ:MYNZ	USA	$4.69 Million

Liability Composition Analysis (2008–2024)

This chart breaks down Pharmena S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Pharmena S.A. (PHR) balance sheet quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	13.52	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.08	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.07	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Pharmena S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Pharmena S.A. (2008–2024)

The table below shows the annual total liabilities of Pharmena S.A. from 2008 to 2024.

Year	Total Liabilities	Change
2024-12-31	zł1.11 Million ≈ $304.39K	-41.97%
2023-12-31	zł1.91 Million ≈ $524.56K	-90.16%
2022-12-31	zł19.37 Million ≈ $5.33 Million	+19.04%
2021-12-31	zł16.27 Million ≈ $4.48 Million	+44.03%
2020-12-31	zł11.30 Million ≈ $3.11 Million	+67.53%
2019-12-31	zł6.74 Million ≈ $1.86 Million	+38.57%
2018-12-31	zł4.87 Million ≈ $1.34 Million	-35.47%
2017-12-31	zł7.54 Million ≈ $2.08 Million	-9.57%
2016-12-31	zł8.34 Million ≈ $2.30 Million	+28.60%
2015-12-31	zł6.49 Million ≈ $1.78 Million	+71.61%
2014-12-31	zł3.78 Million ≈ $1.04 Million	+50.80%
2013-12-31	zł2.51 Million ≈ $689.69K	-3.98%
2012-12-31	zł2.61 Million ≈ $718.31K	+63.31%
2011-12-31	zł1.60 Million ≈ $439.83K	+75.05%
2010-12-31	zł912.97K ≈ $251.26K	-2.34%
2009-12-31	zł934.89K ≈ $257.29K	+27.15%
2008-12-31	zł735.26K ≈ $202.35K	--

About Pharmena S.A.

WAR:PHR Poland Biotechnology

Market Cap

$9.50 Million

zł34.53 Million PLN

Market Cap Rank

#27282 Global

#290 in Poland

Share Price

zł3.10

Change (1 day)

+0.00%

52-Week Range

zł2.55 - zł4.22

All Time High

zł28.01